CANADA LIFE ASSURANCE Co Has $21.95 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

CANADA LIFE ASSURANCE Co grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,454 shares of the medical instruments supplier’s stock after purchasing an additional 918 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.08% of West Pharmaceutical Services worth $21,948,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Evoke Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the fourth quarter worth approximately $7,770,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of West Pharmaceutical Services by 1.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock worth $75,766,000 after acquiring an additional 2,759 shares during the period. International Assets Investment Management LLC lifted its stake in shares of West Pharmaceutical Services by 13,230.0% in the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock worth $6,571,000 after acquiring an additional 18,522 shares during the period. Vanguard Group Inc. lifted its stake in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after acquiring an additional 104,740 shares during the period. Finally, Mizuho Markets Americas LLC lifted its stake in shares of West Pharmaceutical Services by 142.3% in the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock worth $11,724,000 after acquiring an additional 17,399 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $277.16 on Friday. The stock’s 50 day moving average is $325.51 and its 200 day moving average is $356.21. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The firm has a market cap of $20.19 billion, a P/E ratio of 36.56, a P/E/G ratio of 5.75 and a beta of 1.00. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $415.73.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.77 by ($0.25). The company had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. West Pharmaceutical Services’s revenue was down 6.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.11 earnings per share. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.